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the 1st-line biologic (EU:74%; US:70%) while 20% and 23% respectively in EU and 
US were on 2nd-line biologic. Per physician-assessment, 49%/41%/9% were mild/
moderate/severe in EU and 59%/35%/6% were mild/moderate/severe in US. Among 
those with available data, recent disease severity scores increased with increas-
ing Physician-assessment-based severity level in both EU and US (mean values for 
mild/moderate/severe): Tender Joint Count - EU:2.5/5.3/7.4 vs. US:2.3/6.6/8.9; Swollen 
Joint Count - EU:1.3/3.6/5.3 vs. US: 1.5/5.0/6.7; 100mm VAS Score - EU:19.8/38.9/51.4 
vs. US:17.2/47.0/48.6; HAQ Score - EU:0.8/1.4/1.5 vs. US:0.7/1.4/1.9; DAS28 score - 
EU:2.6/4.1/5.1 vs. US:2.5/4.0/5.3; Total Sharp Score - EU: 2.4/2.1/4.0 vs. US:3.1/2.3/7.0. 
Person correlation coefficient (r) comparing PGA (mild:1, modearate:2, severe:3) to 
individual objective disease severity measures were in the range of 0.79-1.00 in EU and 
0.77-1.00 in US. CONCLUSIONS: Across the geographies, physician-assessment (per 
clinical judgment) strongly correlated with the objective measures of disease severity 
among RA patients, further strengthening the argument towards continued inclusion/
use of simple physician-assessment scales in usual care practices around the world.
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OBJECTIVES: To compare RA patients on disease remission in the EU and US among 
those receiving a biologic treatment as part of usual care. METHODS: A multi-
country multi-center medical chart-review study of RA patients was conducted in 
4Q2011 among physicians (majority: rheumatologists) in hospitals/private practices 
to collect de-identified data on patients who were recently treated with a biologic 
as part of usual care. Physicians were screened for practice-duration and patient-
volume and recruited from a large panel to be geographically representative in the 
EU (UK/Germany/France/Italy/Spain) and US. For each study-eligible patient chart, 
physicians abstracted patient diagnosis, treatment patterns/dynamics and patient 
symptomatology/disease status (incl. assessment of ‘disease remission’, per physi-
cian clinical judgment (both objective & subjective)). Patients on disease remission 
were analyzed. RESULTS: Analysis included 1161 and 405 patients experiencing 
disease remission in the EU and US respectively; 75% (vs. 74%), 20% (vs. 22%) and 
5% (vs. 4%) were on 1st line, 2nd line and > = 3rdline biologic respectively in the EU 
(vs. US). Mean duration in remission was: EU-12.2mo vs. US-12.1mo. Among those 
with lab measures, results were mostly similar between patients in remission in 
the EUvs.US: mean ESR(mm/h): 17.0vs.18.9, mean CRP(mg/dl): 7.0vs.1.6, Rheumatoid 
Factor (% positive): 83%vs.87% and Anti-CCP (% positive): 75%vs.74%. Among 
those with available data, recent (mean) disease severity scores were also similar 
between patients in remission in the EUvs.US: Tender Joint Count: 2.3vs.1.7, Swollen 
Joint Count: 1.2vs.0.8, 100mm VAS score: 18.6vs.18.9, HAQ: 0.7vs.0.6 and DAS28: 
2.6vs.2.2. CONCLUSIONS: This is one of the first studies to compare RA patients in 
remission in the EU and US; the characteristics of these RA patients in remission 
were found mostly similar between these geographic clusters, despite the potential 
variations in healthcare systems and modalities of care delivery, possibly attributed 
by ACR/EULAR efforts in standardizing the outcome definitions and care delivery.
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OBJECTIVES: To assess the patterns of disease remission among Rheumatoid 
Arthritis (RA) patients recently treated with biologic therapies in Japan. METHODS: 
A multi-center medical chart-review study of RA patients was conducted among 
physicians (rheumatologists) in hospitals/private practices to collect de-identified 
data on patients who were currently on a biologic or recently discontinued a bio-
logic within past 3-months. Physicians were screened for practice-duration and 
patient-volume and recruited from a large panel to be geographically representa-
tive of Japan. Patient charts of ~10 successive patients visiting each center/prac-
tice during study period were selected. Physicians abstracted patient diagnosis, 
treatment patterns/dynamics and patient symptomatology/disease status (incl. 
assessment of ‘disease remission’, per physician clinical judgment (both objective 
& subjective)). RESULTS: In 4Q2011, physicians abstracted 435 eligible RA patient 
charts; 79%, 17%and 3% were on 1st line, 2nd line and 3rd line biologic respectively. 
Overall, 49% of patients were in remission; the mean duration of remission sta-
tus was 16.7 months. Remission-rate differed by biologic lines: 1st-line:53%, 2nd-
line:41%, 3rd-line:21%. Among those with lab measures, results differed between 
those in remission vs. those who were not: mean ESR(mm/h): 18.1vs.30.6, mean 
CRP(mg/dl): 0.5vs.1.2, mean MMP3(ng/ml): 84.7-vs-136.7, Rheumatoid Factor (% 
positive): 87%-vs-91% and Anti-CCP (% positive): 91%-vs-94%. Among those with 
available data, recent (mean) disease severity scores differed between those in 
remission vs. those who were not: Tender Joint Count: 0.8-vs-2.7, Swollen Joint 
Count: 0.8-vs-2.6, 100mm VAS score: 12.8-vs-32.2, HAQ: 0.1-vs-0.2 and DAS28: 1.8-
vs-3.7. CONCLUSIONS: Approximately half of the patients were not in remission 
in this cohort of RA patients in Japan who were treated with a biologic; they experi-
enced disproportionate level of disease burden. As the line of treatment increased, 
proportion of individuals achieving remission decreased. These observed patterns 
warrant further scrutiny to determine the best practices and improve remission 
rates, thereby alleviating patient burden.
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effectively target interventions to improve arthritis management in the Medicare 
managed care population.
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OBJECTIVES: To describe prevalence and to evaluate pattern of use and sanitary 
costs of patients treated with osteoporosis drugs, using advanced reporting tools 
and methodologies integrating Big Data (coreReports) METHODS: Starting from 
ARNO Observatory, an Italian Database that collects health data on a population 
of 13 million Italian citizens, a new automated analytical tools (CoreReports) has 
been developed in order to manage, catalog and find the strategic indicators of 
healthcare costs and patients care pathways related to Diseases, Populations, Drugs 
with benchmarking among different geographical areas. All web-based Reports are 
automatically generated on-the-fly according to analytical needs and validated by 
a Scientific Committee with experts in various diseases. Among different diseases 
some results related to osteoporosis will be presented. RESULTS: Of the 5,364,167 
subjects over 40 years, 176,831 (prevalence 3.3%) were treated with osteoporosis 
drugs with the following pattern of use: bisphosphonates (80%), strontium ranela-
tum (18%), parathyroid hormone (1.2%), SERMs (0.8%), denosumab (0.4%). A consid-
erable percentage (21.8%) didn’t received vitamin D supplements in association. 
Patients with osteoporosis received many drugs expression of comorbidity (car-
diovascular drugs 67% of patients, corticosteroids 25%, nervous system drugs 33%). 
More than 1/6 of patients were hospitalized during 2012 (fractures 2,2%). Less than 
50% of patients controlled their serum calcium levels in the last three years, 34% per-
formed a densitometry. The average yearly cost/patient is 2.332€ , 37% due to drugs 
(30% specific drugs, 70% others), 45% due to hospitalization and 18.8% to lab tests 
and diagnostic examinations. CONCLUSIONS: Osteoporosis represents a condition 
of high epidemiological prevalence and with a strong impact on the social welfare, 
on prevention and on pharmaceutical costs. A big data infrastructure represents a 
tool to evaluate patient care pathways with osteoporosis and estimate cost of illness 
and can be a valid instrument to support clinical governance
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OBJECTIVES: Despite an estimated 2 million osteoporosis (OP)-related fractures occur-
ring annually, achievement of post-fracture OP quality measures is low. In 2013, the 
national average pass rate on the Healthcare Effectiveness Data and Information Set 
(HEDIS) measure “Osteoporosis Management in Women who had a Fracture” was 23%. 
This study has sought to identify characteristics associated with success or failure in 
meeting the current OP HEDIS measure. METHODS: Women were included if they 
were between 67-85 years (yrs) of age, had ≥ 1 fracture from July 2011 to December 
2013 (index date = earliest encounter), and were continuously enrolled in a Humana 
Medicare Advantage with Prescription Drug coverage (MAPD) plan for at least 12 
months pre-index and 6 months post-index. Patients were excluded if they had a 
BMD (bone mineral density) test or OP treatment pre-index. Descriptive statistics 
were compiled for the following variables: age, race, geographic region, and insurance 
type. RESULTS: The sample included 52,864 women. Mean age among the 17,952 (34%) 
patients who “passed” and the 34,912 (66%) who “failed” the HEDIS measure was 76.3 
yrs and 76.1 yrs respectively (p= 0.0003). A higher percentage of black women were 
in the “failed” group (6.2% failed vs. 5.4% passed; p< 0.0001), while Hispanic women 
were more prevalent in the “passed” group (3.0% passed vs. 1.3% failed; p< 0.0001). A 
larger proportion of patients residing in the Midwest were in the “failed” group (27.3% 
failed vs. 19.3% passed; p< 0.0001), along with those in suburban (26.5% failed vs. 19.6% 
passed; p< 0.0001) and rural (12.5% failed vs. 7.8% passed; p< 0.0001) areas. A greater 
fraction of women who “passed” the measure (69.9% passed vs. 60.6% failed; p< 0.0001) 
resided in the South. CONCLUSIONS: Preliminary results identify characteristics of 
women with OP who are receiving suboptimal care. Further analyses could enable 
targeting of at-risk women to improve post-fracture OP management.
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OBJECTIVES: To evaluate the relationship between physician-assessment (per clini-
cal judgment) and objective measures for disease severity assessments among RA 
patients in the EU and US. METHODS: A multi-country multi-center medical chart-
review study of RA patients was conducted in 4Q2011 among physicians (major-
ity: rheumatologists) in hospitals/private practices to collect de-identified data on 
patients who were recently treated with a biologic as part of usual care. Physicians 
were screened for practice-duration and patient-volume and recruited from a large 
panel to be geographically representative in the EU (UK/Germany/France/Italy/Spain) 
and US. For successive patients visiting each center/practice during study period, 
physicians abstracted patient diagnosis, treatment patterns/dynamics and patient 
symptomatology/disease status incl. physician-assessment of disease severity (rated 
as mild/moderate/severe, per clinical judgment). RESULTS: In EU and US, 2208 and 
851 patient charts were abstracted respectively; majority of the patients were on 
